Skip to content

Source filing unavailable

Q4 2012 · —
Revenue$33.00Kno prior Q4 2011 on file−2.9% vs Q3 2012
Net income—
EPS Diluted-$2.08no prior Q4 2011 on fileN/M vs Q3 2012
Operating Income-$4,238,000—
Operating Cash Flowderived-$3,976,000—
Free Cash Flowderived-$3,976,000—
Margins · derived
Operating margin-12842.4%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q4 2011 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR